|
G |
Arhgap45 |
Rho GTPase activating protein 45 |
affects expression |
ISO |
cefepime affects the expression of ARHGAP45 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
cefepime inhibits the reaction [Amikacin results in decreased activity of CAT protein] |
CTD |
PMID:18781908 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases activity |
ISO |
cefepime results in decreased activity of DHFR protein |
CTD |
PMID:25418905 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
cefepime results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
affects expression |
ISO |
cefepime affects the expression of HLA-DRB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Cefotaxime results in increased expression of BAX protein |
CTD |
PMID:15012731 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Cefotaxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:16939481 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Cefotaxime results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
affects expression |
ISO |
Cefotaxime affects the expression of HLA-F mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,403,418...3,479,476
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Cefotaxime results in increased expression of TP53 protein |
CTD |
PMID:15012731 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Defb5 |
defensin beta 5 |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein] |
CTD |
PMID:27397760 PMID:28720485 |
|
NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]] |
CTD |
PMID:27397760 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein] |
CTD |
PMID:27397760 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein] |
CTD |
PMID:28720485 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein] |
CTD |
PMID:28720485 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Ceftazidime |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases activity |
ISO |
Ceftazidime results in decreased activity of DHFR protein |
CTD |
PMID:25418905 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
Ceftazidime results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:16939481 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
EXP |
Ceftriaxone results in decreased expression of ACE2 mRNA |
CTD |
PMID:29745864 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Actb |
actin, beta |
increases expression |
EXP |
Ceftriaxone results in increased expression of ACTB mRNA |
CTD |
PMID:29745864 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Bace1 |
beta-secretase 1 |
decreases expression |
EXP |
Ceftriaxone results in decreased expression of BACE1 mRNA |
CTD |
PMID:29745864 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Cat |
catalase |
decreases expression multiple interactions |
ISO EXP |
Ceftriaxone results in decreased expression of CAT protein Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]] |
CTD |
PMID:19442074 PMID:25053526 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases activity |
ISO |
Ceftriaxone results in decreased activity of DHFR protein |
CTD |
PMID:25418905 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
increases expression |
EXP |
Ceftriaxone results in increased expression of ECE1 mRNA |
CTD |
PMID:29745864 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Epo |
erythropoietin |
increases expression |
EXP |
Ceftriaxone results in increased expression of EPO mRNA |
CTD |
PMID:29745864 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Ide |
insulin degrading enzyme |
increases expression |
EXP |
Ceftriaxone results in increased expression of IDE mRNA |
CTD |
PMID:29745864 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]] |
CTD |
PMID:25053526 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mme |
membrane metallo-endopeptidase |
increases expression |
EXP |
Ceftriaxone results in increased expression of MME mRNA |
CTD |
PMID:29745864 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions increases expression |
EXP |
Ceftriaxone inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of SLC1A2 protein]; Ceftriaxone inhibits the reaction [Cocaine results in decreased expression of SLC1A2 protein]; Ceftriaxone inhibits the reaction [JZL195 results in decreased expression of and affects the folding of SLC1A2 protein]; Ceftriaxone promotes the reaction [Kainic Acid results in increased expression of SLC1A2 protein] Ceftriaxone results in increased expression of SLC1A2 protein |
CTD |
PMID:19625514 PMID:19717140 PMID:28257918 PMID:29045497 PMID:29432698 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
EXP |
Ceftriaxone inhibits the reaction [Cocaine results in decreased expression of SLC7A11 protein] |
CTD |
PMID:19717140 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]] |
CTD |
PMID:25053526 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cat |
catalase |
decreases activity |
EXP |
Cefuroxime results in decreased activity of CAT protein |
CTD |
PMID:30797828 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Cefuroxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:16939481 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases activity |
ISO |
Cefuroxime results in decreased activity of NFE2L2 protein |
CTD |
PMID:30203046 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases activity |
ISO |
Cefuroxime results in decreased activity of NR1I3 protein |
CTD |
PMID:30203046 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases activity |
ISO |
Cefuroxime results in decreased activity of PPARA protein |
CTD |
PMID:30203046 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Cefuroxime affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Cefuroxime affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Sulfur co-treated with zoxamide co-treated with cyflufenamid] results in decreased expression of BAX mRNA |
CTD |
PMID:35564597 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
[2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein; Resveratrol inhibits the reaction [[2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein] |
CTD |
PMID:37009748 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:30818834 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; fluoxastrobin inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
fluoxastrobin results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
fluoxastrobin results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [Rosiglitazone results in increased activity of PPARG protein] |
CTD |
PMID:30818834 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
fluoxastrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Fluvoxamine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1A protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Fluvoxamine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Avp |
arginine vasopressin |
increases expression |
ISO |
Fluvoxamine results in increased expression of AVP protein |
CTD |
PMID:11195401 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Fluvoxamine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Fluvoxamine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Fluvoxamine results in decreased activity of CYP19A1 protein |
CTD |
PMID:26162595 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity increases response to substance |
ISO EXP |
[Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Phenacetin; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in increased chemical synthesis of Aconitine metabolite; CYP1A2 protein binds to and affects the metabolism of Fluvoxamine; Enoxacin inhibits the reaction [CYP1A2 protein affects the metabolism of Fluvoxamine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of olanzapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of Theophylline]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of Acetaminophen]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of clozapine N-oxide]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of norclozapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Caffeine CYP1A2 protein results in increased susceptibility to Fluvoxamine |
CTD |
PMID:9029748 PMID:11763009 PMID:15545309 PMID:15845683 PMID:15905806 PMID:18809730 PMID:18816299 PMID:21277363 PMID:21915887 PMID:26599973 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein |
CTD |
PMID:15967061 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects response to substance |
ISO |
HTR2A gene SNP affects the susceptibility to Fluvoxamine |
CTD |
PMID:12607287 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA] Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Terfenadine co-treated with Fluvoxamine] binds to and results in decreased activity of KCNH2 protein; Fluvoxamine binds to and results in decreased activity of KCNH2 protein; Fluvoxamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Fluvoxamine results in decreased activity of KCNH2 protein |
CTD |
PMID:20071423 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
Fluvoxamine results in increased expression of NOS2 mRNA Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA] Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA] |
CTD |
PMID:12429386 PMID:27803785 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein |
CTD |
PMID:15967061 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
decreases activity affects response to substance |
ISO |
Fluvoxamine results in decreased activity of SCN5A protein SCN5A protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:19875396 |
|
NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP ISO |
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
kresoxim-methyl inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
kresoxim-methyl inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; kresoxim-methyl inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases activity |
ISO |
kresoxim-methyl results in decreased activity of GPX1 protein |
CTD |
PMID:30064279 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
kresoxim-methyl results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
kresoxim-methyl inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
kresoxim-methyl inhibits the reaction [Rosiglitazone results in increased activity of PPARG protein] |
CTD |
PMID:30818834 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
kresoxim-methyl inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Thrb |
thyroid hormone receptor beta |
affects binding |
ISO |
kresoxim-methyl binds to THRB protein |
CTD |
PMID:28973306 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tp53 |
tumor protein p53 |
increases activity |
ISO |
kresoxim-methyl results in increased activity of TP53 protein |
CTD |
PMID:30818834 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
oxiconazole results in decreased activity of CYP19A1 protein |
CTD |
PMID:24496634 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA] oxiconazole results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17998298 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
oxiconazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
oxiconazole results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]] |
CTD |
PMID:17998298 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions decreases expression decreases activity |
ISO |
oxiconazole binds to and results in increased activity of NR1I2 protein; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]; oxiconazole promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA] oxiconazole results in decreased expression of NR1I2 mRNA oxiconazole results in decreased activity of NR1I2 protein |
CTD |
PMID:17438109 PMID:17998298 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
oxiconazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:30818834 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
trifloxystrobin results in increased expression of BECN1 protein |
CTD |
PMID:27853101 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Dnm1l |
dynamin 1-like |
increases phosphorylation multiple interactions |
ISO |
trifloxystrobin results in increased phosphorylation of DNM1L protein MitoTEMPO inhibits the reaction [trifloxystrobin results in increased phosphorylation of DNM1L protein] |
CTD |
PMID:27853101 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; trifloxystrobin inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
trifloxystrobin results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
increases expression |
ISO |
trifloxystrobin results in increased expression of LAMP2 protein |
CTD |
PMID:27853101 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
trifloxystrobin results in increased expression of MAP1LC3B protein alternative form |
CTD |
PMID:27853101 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
trifloxystrobin results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
trifloxystrobin results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pink1 |
PTEN induced kinase 1 |
increases expression multiple interactions |
ISO |
trifloxystrobin results in increased expression of PINK1 protein MitoTEMPO inhibits the reaction [trifloxystrobin results in increased expression of PINK1 protein] |
CTD |
PMID:27853101 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
trifloxystrobin inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
increases expression multiple interactions |
ISO |
trifloxystrobin results in increased expression of PRKN protein MitoTEMPO inhibits the reaction [trifloxystrobin results in increased expression of PRKN protein] |
CTD |
PMID:27853101 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|